Skip to main content

Breast Cancer Research and Treatment

Ausgabe 1/2012

Inhalt (41 Artikel)

Review

Risk prediction models of breast cancer: a systematic review of model performances

Thunyarat Anothaisintawee, Yot Teerawattananon, Chollathip Wiratkapun, Vijj Kasamesup, Ammarin Thakkinstian

Review

Role of interleukin-10 in breast cancer

Hamidullah, Bendangla Changkija, Rituraj Konwar

Preclinical Study

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas

Preclinical Study

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients

Johanna G. H. van Nes, Esther M. de Kruijf, Hein Putter, Dana Faratian, Alison Munro, Fiona Campbell, Vincent T. H. B. M. Smit, Gerrit-Jan Liefers, Peter J. K. Kuppen, Cornelis J. H. van de Velde, John M. S. Bartlett

Preclinical Study

Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer

Vera Moura, Manuela Lacerda, Paulo Figueiredo, Maria L. Corvo, Maria E. M. Cruz, Raquel Soares, Maria C. Pedroso de Lima, Sérgio Simões, João N. Moreira

Preclinical study

Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy

C. Panis, A. C. S. A. Herrera, V. J. Victorino, F. C. Campos, L. F. Freitas, T. De Rossi, A. N. Colado Simão, A. L. Cecchini, R. Cecchini

Preclinical study

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

Wenjie Jessie Lu, Cong Xu, Zifan Pei, Abdelrahman S. Mayhoub, Mark Cushman, David A. Flockhart

PRECLINICAL STUDY

RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer

Min He, Gen-Hong Di, A-Yong Cao, Zhen Hu, Wei Jin, Zhen-Zhou Shen, Zhi-Ming Shao

Preclinical study

Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1

Hongmei Zeng, Melinda L. Irwin, Lingeng Lu, Harvey Risch, Susan Mayne, Lina Mu, Qian Deng, Luca Scarampi, Marco Mitidieri, Dionyssios Katsaros, Herbert Yu

Preclinical Study

Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus

Paul E. Goss, Shangle Qi, Haiqing Hu, Lalji K. Gediya, Puranik Purushottamachar, Abhijit M. Godbole, Vincent C. O. Njar

Preclinical Study

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer

Tokiko Ito, Shinobu Kamijo, Hiroto Izumi, Kimitoshi Kohno, Jun Amano, Ken-ichi Ito

Preclinical Study

Genetic heterogeneity in HER2 testing may influence therapy eligibility

Barbara Bernasconi, Anna Maria Chiaravalli, Giovanna Finzi, Katia Milani, Maria Grazia Tibiletti

Preclinical Study

Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues

Amy C. Degnim, Daniel W. Visscher, Tanya L. Hoskin, Marlene H. Frost, Robert A. Vierkant, Celine M. Vachon, V. Shane Pankratz, Derek C. Radisky, Lynn C. Hartmann

Preclinical study

Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients

Emmi Peurala, Peppi Koivunen, Risto Bloigu, Kirsi-Maria Haapasaari, Arja Jukkola-Vuorinen

Preclinical study

Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis

Dong Yang, Yongchao Zhao, Amy Y. Li, Shaomeng Wang, Gongxian Wang, Yi Sun

Preclinical study

Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment

Brant Pohorelic, R. Singh, S. Parkin, K. Koro, A.-D. Yang, C. Egan, A. Magliocco

Erratum

Erratum to: Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment

Brant Pohorelic, R. Singh, S. Parkin, K. Koro, A.-D. Yang, C. Egan, A. Magliocco

Clinical trial

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

Irene Kuter, Julia M. W. Gee, Roberto Hegg, Christian F. Singer, Rajendra A. Badwe, Elizabeth S. Lowe, Ugochi A. Emeribe, Elizabeth Anderson, Francisco Sapunar, Pauline Finlay, Robert I. Nicholson, José Bines, Nadia Harbeck

Clinical trial

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?

Yeon Hee Park, Seock-Ah Im, Eun Yoon Cho, Yoon-La Choi, Jeong Eon Lee, Seok Jin Nam, Jung Hyun Yang, Jin Seok Ahn, Young-Hyuck Im

Clinical Trial

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Else Maae, Dorte Aalund Olsen, Karina Dahl Steffensen, Erik Hugger Jakobsen, Ivan Brandslund, Flemming Brandt Sørensen, Anders Jakobsen

Clinical trial

Prospective study of breast tomosynthesis as a triage to assessment in screening

Daniela Bernardi, Stefano Ciatto, Marco Pellegrini, Paolina Tuttobene, Carmine Fanto’, Marvi Valentini, Stefano Di Michele, Paolo Peterlongo, Nehmat Houssami

Epidemiology

Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin

Gorka Ruiz de Garibay, Sara Gutiérrez-Enríquez, Pilar Garre, Sandra Bonache, Atocha Romero, Laura Palomo, Ana Sánchez de Abajo, Javier Benítez, Judith Balmaña, Pedro Pérez-Segura, Eduardo Díaz-Rubio, Orland Díez, Trinidad Caldés, Miguel de la Hoya

Epidemiology

Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US

Joseph Lipscomb, Theresa W. Gillespie, Michael Goodman, Lisa C. Richardson, Lori A. Pollack, A. Blythe Ryerson, Kevin C. Ward

Epidemiology

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

Derek Weycker, Rich Barron, John Edelsberg, Alex Kartashov, Gary H. Lyman

Epidemiology

Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers

Seho Park, Hyung Seok Park, Ja Seung Koo, Woo Ick Yang, Seung Il Kim, Byeong-Woo Park

Epidemiology

Favorable outcome associated with an IGF-1 ligand signature in breast cancer

Lina Mu, David Tuck, Dionyssios Katsaros, Lingeng Lu, Vincent Schulz, Sudhir Perincheri, Guido Menato, Luca Scarampi, Lyndsay Harris, Herbert Yu

Epidemiology

Structural/organizational characteristics of health services partly explain racial variation in timeliness of radiation therapy among elderly breast cancer patients

Stephanie B. Wheeler, William R. Carpenter, Jeffrey Peppercorn, Anna P. Schenck, Morris Weinberger, Andrea K. Biddle

Epidemiology

Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

Swati Biswas, Neelam Tankhiwale, Amanda Blackford, Angelica M. Gutierrez Barrera, Kaylene Ready, Karen Lu, Christopher I. Amos, Giovanni Parmigiani, Banu Arun

Epidemiology

Willingness to use tamoxifen to prevent breast cancer among diverse women

Celia Patricia Kaplan, Sue E. Kim, Sabrina T. Wong, George F. Sawaya, Judith M. E. Walsh, Eliseo J. Pérez-Stable

Epidemiology

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Annette Wigertz, Johan Ahlgren, Marit Holmqvist, Tommy Fornander, Jan Adolfsson, Henrik Lindman, Leif Bergkvist, Mats Lambe

Epidemiology

Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis

Candyce H. Kroenke, Yvonne Michael, Hilary Tindle, Elizabeth Gage, Rowan Chlebowski, Lorena Garcia, Catherine Messina, JoAnn E. Manson, Bette J. Caan

Brief Report

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)

Hatem A. Azim Jr., Otto Metzger-Filho, Evandro de Azambuja, Sibylle Loibl, Florine Focant, Ekaterina Gresko, Mounir Arfi, Martine Piccart-Gebhart

Brief Report

Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing

K. De Leeneer, M. Van Bockstal, S. De Brouwer, N. Swietek, P. Schietecatte, N. Sabbaghian, J. Van den Ende, S. Willocx, K. Storm, B. Blaumeiser, C. J. Van Asperen, J. T. Wijnen, K. Leunen, E. Legius, G. Michils, G. Matthijs, M. J. Blok, E. Gomez-Garcia, A. De Paepe, M. Tischkowitz, B. Poppe, K. Claes

Erratum

Erratum to: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

Sean D. McAllister, Ryuichi Murase, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Juanita Allison, Carolina Almanza, Arash Pakdel, Jasmine Lee, Chandani Limbad, Yong Liu, Robert J. Debs, Dan H. Moore, Pierre-Yves Desprez

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.